Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)

INTRODUCTION: High HIV incidence and low adherence to daily oral PrEP among women underscore the need for more acceptable and easier to use HIV prevention products. Global demand for injectable contraception suggests that new, long‐acting, injectable formulations could meet this need. We examine acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolley, Elizabeth E, Li, Sue, Zangeneh, Sahar Z, Atujuna, Millicent, Musara, Petina, Justman, Jessica, Pathak, Subash, Bekker, Linda‐Gail, Swaminathan, Shobha, Stanton, Jill, Farrior, Jennifer, Sista, Nirupama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813716/
https://www.ncbi.nlm.nih.gov/pubmed/31651098
http://dx.doi.org/10.1002/jia2.25408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813716/
https://www.ncbi.nlm.nih.gov/pubmed/31651098
http://dx.doi.org/10.1002/jia2.25408

Ejemplares similares